A Phase 1/2 Study Of CPI-0209 Monotherapy And In Combination With Other Therapy In Patients With Advanced Tumors Read more
Master Study: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naïve Patients with Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A) – NCT04165070 KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B) – NCT04165083 KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy (MK-3475-01C) – NCT04165096 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Read more
A Multi-Center, Open Label Phase 1/2 Study Of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors Read more
A Phase 1 Open Label, Multi-Arm, Multicenter Study Of MK-4830 As Monotherapy And In Combination With Pembrolizumab For Participants With Advanced Solid Tumors Read more
A Phase 1b, Multicenter, 2-Part, Open-Label Study Of DS-1062a In Combination With Durvalumab In Subjects With Advanced Or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations And Previously Treated With Platinum-Based Chemotherapy With Or Without Prior Immunotherapy Read more
A Phase 1 Trial Of MK-7684 As Monotherapy And In Combination With Pembrolizumab In Subjects With Advanced Solid Tumors Read more
Phase I/II, Two-Part, Multicenter First-In-Human Study Of DS-7300a In Subjects With Advanced Solid Malignant Tumors Read more
Phase 1b/2, Open-Label, Multicenter Study Of ERAS-007 In Combination With Other Anti-Cancer Therapies In Patients With Advanced Non-Small-Cell Lung Cancer (HERKULES-2) Read more
Long-Term, Non-Interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy Read more
